 | • レポートコード：GIR201107493 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、原発性胆汁性肝硬変治療薬の世界市場を調査対象にし、原発性胆汁性肝硬変治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ブデソニド、FFP-104、GSK-2330672、MBX-8025、NGM-282、その他）、用途別分析（クリニック、病院、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：AlbireoPharma、MediGene AG、Enanta Pharmaceuticals, Inc.、CymaBay Therapeutics, Inc.、Johnson & Johnson、Dr. Falk Pharma GmbH、Virobay Inc.、Intercept Pharmaceuticals, Inc.、GlaxoSmithKline Plc、NGM Biopharmaceuticals, Inc. ・メーカー別販売量、売上、市場シェア ・原発性胆汁性肝硬変治療薬の地域別市場分析 ・原発性胆汁性肝硬変治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・原発性胆汁性肝硬変治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・原発性胆汁性肝硬変治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・原発性胆汁性肝硬変治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・原発性胆汁性肝硬変治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・原発性胆汁性肝硬変治療薬の種類別市場規模2015-2020：ブデソニド、FFP-104、GSK-2330672、MBX-8025、NGM-282、その他 ・原発性胆汁性肝硬変治療薬の用途別市場規模2015-2020：クリニック、病院、その他 ・原発性胆汁性肝硬変治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Primary Biliary Cirrhosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Primary Biliary Cirrhosis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Primary Biliary Cirrhosis Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Primary Biliary Cirrhosis Drug market has been segmented into
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
By Application, Primary Biliary Cirrhosis Drug has been segmented into:
Clinic
Hospital
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Primary Biliary Cirrhosis Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Primary Biliary Cirrhosis Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Primary Biliary Cirrhosis Drug market.
The report offers in-depth assessment of the growth and other aspects of the Primary Biliary Cirrhosis Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Primary Biliary Cirrhosis Drug Market Share Analysis
Primary Biliary Cirrhosis Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Primary Biliary Cirrhosis Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Primary Biliary Cirrhosis Drug sales, revenue and market share for each player covered in this report.
The major players covered in Primary Biliary Cirrhosis Drug are:
AlbireoPharma
MediGene AG
Enanta Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
Johnson & Johnson
Dr. Falk Pharma GmbH
Virobay Inc.
Intercept Pharmaceuticals, Inc.
GlaxoSmithKline Plc
NGM Biopharmaceuticals, Inc.
Among other players domestic and global, Primary Biliary Cirrhosis Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Primary Biliary Cirrhosis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Primary Biliary Cirrhosis Drug, with price, sales, revenue and global market share of Primary Biliary Cirrhosis Drug in 2018 and 2019.
Chapter 3, the Primary Biliary Cirrhosis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Primary Biliary Cirrhosis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Primary Biliary Cirrhosis Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Primary Biliary Cirrhosis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Primary Biliary Cirrhosis Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Primary Biliary Cirrhosis Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Budesonide
1.2.3 FFP-104
1.2.4 GSK-2330672
1.2.5 MBX-8025
1.2.6 NGM-282
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Primary Biliary Cirrhosis Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Overview of Global Primary Biliary Cirrhosis Drug Market
1.4.1 Global Primary Biliary Cirrhosis Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AlbireoPharma
2.1.1 AlbireoPharma Details
2.1.2 AlbireoPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AlbireoPharma SWOT Analysis
2.1.4 AlbireoPharma Product and Services
2.1.5 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 MediGene AG
2.2.1 MediGene AG Details
2.2.2 MediGene AG Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 MediGene AG SWOT Analysis
2.2.4 MediGene AG Product and Services
2.2.5 MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Enanta Pharmaceuticals, Inc.
2.3.1 Enanta Pharmaceuticals, Inc. Details
2.3.2 Enanta Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Enanta Pharmaceuticals, Inc. SWOT Analysis
2.3.4 Enanta Pharmaceuticals, Inc. Product and Services
2.3.5 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 CymaBay Therapeutics, Inc.
2.4.1 CymaBay Therapeutics, Inc. Details
2.4.2 CymaBay Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 CymaBay Therapeutics, Inc. SWOT Analysis
2.4.4 CymaBay Therapeutics, Inc. Product and Services
2.4.5 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Johnson & Johnson SWOT Analysis
2.5.4 Johnson & Johnson Product and Services
2.5.5 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Dr. Falk Pharma GmbH
2.6.1 Dr. Falk Pharma GmbH Details
2.6.2 Dr. Falk Pharma GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Dr. Falk Pharma GmbH SWOT Analysis
2.6.4 Dr. Falk Pharma GmbH Product and Services
2.6.5 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Virobay Inc.
2.7.1 Virobay Inc. Details
2.7.2 Virobay Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Virobay Inc. SWOT Analysis
2.7.4 Virobay Inc. Product and Services
2.7.5 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Intercept Pharmaceuticals, Inc.
2.8.1 Intercept Pharmaceuticals, Inc. Details
2.8.2 Intercept Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Intercept Pharmaceuticals, Inc. SWOT Analysis
2.8.4 Intercept Pharmaceuticals, Inc. Product and Services
2.8.5 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 GlaxoSmithKline Plc
2.9.1 GlaxoSmithKline Plc Details
2.9.2 GlaxoSmithKline Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 GlaxoSmithKline Plc SWOT Analysis
2.9.4 GlaxoSmithKline Plc Product and Services
2.9.5 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 NGM Biopharmaceuticals, Inc.
2.10.1 NGM Biopharmaceuticals, Inc. Details
2.10.2 NGM Biopharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 NGM Biopharmaceuticals, Inc. SWOT Analysis
2.10.4 NGM Biopharmaceuticals, Inc. Product and Services
2.10.5 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Primary Biliary Cirrhosis Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Primary Biliary Cirrhosis Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Primary Biliary Cirrhosis Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Primary Biliary Cirrhosis Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Primary Biliary Cirrhosis Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Primary Biliary Cirrhosis Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
4.3 Europe Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
4.5 South America Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Country
5.1.1 North America Primary Biliary Cirrhosis Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Primary Biliary Cirrhosis Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
5.3 Canada Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Primary Biliary Cirrhosis Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Primary Biliary Cirrhosis Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
6.3 UK Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
6.4 France Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
6.5 Russia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
6.6 Italy Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Primary Biliary Cirrhosis Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7.3 Japan Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7.4 Korea Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7.5 India Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
7.7 Australia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Country
8.1.1 South America Primary Biliary Cirrhosis Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Primary Biliary Cirrhosis Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Primary Biliary Cirrhosis Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Primary Biliary Cirrhosis Drug Sales and Market Share by Type (2015-2020)
10.2 Global Primary Biliary Cirrhosis Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Primary Biliary Cirrhosis Drug Price by Type (2015-2020)
11 Global Primary Biliary Cirrhosis Drug Market Segment by Application
11.1 Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
11.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2015-2020)
11.3 Global Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Primary Biliary Cirrhosis Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Primary Biliary Cirrhosis Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Primary Biliary Cirrhosis Drug Market Forecast (2021-2025)
12.2.2 Europe Primary Biliary Cirrhosis Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Primary Biliary Cirrhosis Drug Market Forecast (2021-2025)
12.2.4 South America Primary Biliary Cirrhosis Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Primary Biliary Cirrhosis Drug Market Forecast (2021-2025)
12.3 Primary Biliary Cirrhosis Drug Market Forecast by Type (2021-2025)
12.3.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Primary Biliary Cirrhosis Drug Market Share Forecast by Type (2021-2025)
12.4 Primary Biliary Cirrhosis Drug Market Forecast by Application (2021-2025)
12.4.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Primary Biliary Cirrhosis Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Primary Biliary Cirrhosis Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Primary Biliary Cirrhosis Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AlbireoPharma Basic Information, Manufacturing Base and Competitors
Table 8. AlbireoPharma Primary Biliary Cirrhosis Drug Major Business
Table 9. AlbireoPharma Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 10. AlbireoPharma SWOT Analysis
Table 11. AlbireoPharma Primary Biliary Cirrhosis Drug Product and Services
Table 12. AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. MediGene AG Basic Information, Manufacturing Base and Competitors
Table 14. MediGene AG Primary Biliary Cirrhosis Drug Major Business
Table 15. MediGene AG Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 16. MediGene AG SWOT Analysis
Table 17. MediGene AG Primary Biliary Cirrhosis Drug Product and Services
Table 18. MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Enanta Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Major Business
Table 21. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 22. Enanta Pharmaceuticals, Inc. SWOT Analysis
Table 23. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 24. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. CymaBay Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 26. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Major Business
Table 27. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 28. CymaBay Therapeutics, Inc. SWOT Analysis
Table 29. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 30. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 32. Johnson & Johnson Primary Biliary Cirrhosis Drug Major Business
Table 33. Johnson & Johnson Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 34. Johnson & Johnson SWOT Analysis
Table 35. Johnson & Johnson Primary Biliary Cirrhosis Drug Product and Services
Table 36. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Dr. Falk Pharma GmbH Basic Information, Manufacturing Base and Competitors
Table 38. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Major Business
Table 39. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 40. Dr. Falk Pharma GmbH SWOT Analysis
Table 41. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product and Services
Table 42. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Virobay Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Virobay Inc. Primary Biliary Cirrhosis Drug Major Business
Table 45. Virobay Inc. Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 46. Virobay Inc. SWOT Analysis
Table 47. Virobay Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 48. Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Intercept Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 50. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Major Business
Table 51. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 52. Intercept Pharmaceuticals, Inc. SWOT Analysis
Table 53. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 54. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
Table 56. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Major Business
Table 57. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 58. GlaxoSmithKline Plc SWOT Analysis
Table 59. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product and Services
Table 60. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. NGM Biopharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Major Business
Table 63. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Total Revenue (USD Million) (2018-2019)
Table 64. NGM Biopharmaceuticals, Inc. SWOT Analysis
Table 65. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product and Services
Table 66. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Primary Biliary Cirrhosis Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 68. Global Primary Biliary Cirrhosis Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Primary Biliary Cirrhosis Drug Sales by Regions (2015-2020) (K Pcs)
Table 70. Global Primary Biliary Cirrhosis Drug Sales Market Share by Regions (2015-2020)
Table 71. Global Primary Biliary Cirrhosis Drug Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Primary Biliary Cirrhosis Drug Sales by Countries (2015-2020) (K Pcs)
Table 73. North America Primary Biliary Cirrhosis Drug Sales Market Share by Countries (2015-2020)
Table 74. North America Primary Biliary Cirrhosis Drug Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020)
Table 76. Europe Primary Biliary Cirrhosis Drug Sales by Countries (2015-2020) (K Pcs)
Table 77. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Countries (2015-2020)
Table 78. Europe Primary Biliary Cirrhosis Drug Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Regions (2015-2020) (K Pcs)
Table 80. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Primary Biliary Cirrhosis Drug Sales by Countries (2015-2020) (K Pcs)
Table 83. South America Primary Biliary Cirrhosis Drug Sales Market Share by Countries (2015-2020)
Table 84. South America Primary Biliary Cirrhosis Drug Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Countries (2015-2020) (K Pcs)
Table 87. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020)
Table 90. Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 91. Global Primary Biliary Cirrhosis Drug Sales Share by Type (2015-2020)
Table 92. Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020) (USD Million)
Table 93. Global Primary Biliary Cirrhosis Drug Revenue Share by Type (2015-2020)
Table 94. Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 95. Global Primary Biliary Cirrhosis Drug Sales Share by Application (2015-2020)
Table 96. Global Primary Biliary Cirrhosis Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 97. Global Primary Biliary Cirrhosis Drug Market Share Forecast by Regions (2021-2025)
Table 98. Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 99. Global Primary Biliary Cirrhosis Drug Market Share Forecast by Type (2021-2025)
Table 100. Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2025)
Table 101. Global Primary Biliary Cirrhosis Drug Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Primary Biliary Cirrhosis Drug Picture
Figure 2. Global Sales Market Share of Primary Biliary Cirrhosis Drug by Type in 2019
Figure 3. Budesonide Picture
Figure 4. FFP-104 Picture
Figure 5. GSK-2330672 Picture
Figure 6. MBX-8025 Picture
Figure 7. NGM-282 Picture
Figure 8. Others Picture
Figure 9. Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2018
Figure 10. Clinic Picture
Figure 11. Hospital Picture
Figure 12. Others Picture
Figure 13. Global Primary Biliary Cirrhosis Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Primary Biliary Cirrhosis Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturer in 2019
Figure 34. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Primary Biliary Cirrhosis Drug Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Primary Biliary Cirrhosis Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Regions (2015-2020)
Figure 41. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Regions in 2018
Figure 42. North America Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
Figure 43. Europe Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
Figure 45. South America Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020)
Figure 47. North America Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Primary Biliary Cirrhosis Drug Sales Market Share by Countries (2015-2020)
Figure 49. North America Primary Biliary Cirrhosis Drug Sales Market Share by Countries in 2018
Figure 50. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Countries in 2018
Figure 52. United States Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Countries in 2019
Figure 58. Germany Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Regions 2019
Figure 66. China Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Primary Biliary Cirrhosis Drug Sales Market Share by Countries in 2019
Figure 73. South America Primary Biliary Cirrhosis Drug Revenue Market Share by Countries in 2019
Figure 74. Brazil Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Primary Biliary Cirrhosis Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Primary Biliary Cirrhosis Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Primary Biliary Cirrhosis Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Primary Biliary Cirrhosis Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Primary Biliary Cirrhosis Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Primary Biliary Cirrhosis Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
オベチコール酸薬の世界市場 2020年 Market Overview The global Obeticholic Acid Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Obeticholic Acid Drug m…- 初代細胞培養の世界市場 2020年 Market Overview The global Primary Cell Culture market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Primary Cell Culture mar…
- 一次進行型多発性硬化症治療の世界市場 2020年 Market Overview The global Primary Progressive Multiple Sclerosis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …
- 一次ニッケルの世界市場 2020年 Market Overview The global Primary Nickel market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Primary Nickel market report p…
- プライマリボタンセルの世界市場 2020年 Market Overview The Primary Button Cell market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…